During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Justin Loke, University of Birmingham, Birmingham, UK. We asked, Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

Historically, patients with TP53 mutations have been known to have adverse prognostic features even after intensive chemotherapy treatment, rendering the option of allogeneic transplantation of little value to the patient. In this video, Loke reviews transplant variables and other prognostic factors affecting the outcomes of patients with TP53AML who have undergone allogeneic transplant.